


## Negative findings of regional cerebral blood flow with $^{99m}\text{Tc}$ -ethyl cysteinate dimer in Susac's syndrome


**To the Editor:** We would like to present a case of Susac's syndrome and explain the role of brain single photon emission tomography (SPET) with acetazolamid enhancement in this rare and important disease.

Susac's syndrome (SS) consists of a noninflammatory microangiopathy which results in a triad of, encephalopathy, branch retinal artery occlusions, and hearing loss [1]. Other neurological manifestations due to multifocal vasculitis are extremely variable and include ataxia, corticospinal tract signs, urinary incontinence and vertigo [2]. The etiology of such an occlusive microangiopathy is unknown and its predilection for the brain, retina, and cochlear has not been adequately elucidated. Brain biopsies have reported sclerosis of the media and adventitia of cortical and pial vessel [3, 4].



**Figure 1.** Fluorescein angiogram showing the segmental arteriolar branch occlusion seen in Susac's retinopathy


The differential diagnosis of SS is broad [5] and includes, multiple sclerosis, aseptic meningitis, systemic lupus erythematosus, Behcet's disease, acute and chronic encephalitis, thromboembolic stroke and complicated migraines. Other diseases like sarcoidosis, tuberculosis, syphilis, systemic lupus erythematosus, antiphospholipid antibody syndrome [APS] and lymphomas should be kept in mind [6].



**Figure 2.** Magnetic resonance imaging of brain showing a few small high signal intensity foci in periventricular white matter on FLAIR (A), T2 weighted images (B) and also in corpus callosum on T2 weighted image (C). These lesions are bright spots on the aforementioned images.

Our case was a 27 years old lady presented with visual impairment of the right eye. The patient had no fever on admission and a general physical condition was normal. Laboratory tests including erythrocyte sedimentation rate, C reactive protein, glycemia, cholesterol, triglyceride levels, liver function tests and urine analysis were within normal limits. Antibody screening tests, i.e. antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, anti-DNA, antismooth muscle antibodies (ASMA) and anti  $\beta 2$  microglobulin, rheumatoid factor and lupus erythematosus cells were negative.

Three months after initiation of the disease, the patient complained of left ear hearing loss and audiometric evaluation demonstrated sensorineural hearing loss and impaired word discrimination. Subsequently, the patient had intermittent sensory and motor signs that resulted in hospital admission where she was treated with corticosteroids.



**Figure 3.** Brain SPET with  $^{99m}\text{Tc}$ -ECD shows no remarkable abnormality.

The acquired electroencephalogram showed no abnormality. The ophthalmologic examination revealed mild pigmentation on the right macula. A primary test showed central scotoma on the right macula congruent with multiple retinal arteriolar branch occlusions on fluorescein angiography (Fig. 1). She was subjected to brain MRI twice with an interval of 4 months that showed only a few tiny high signal intensity foci in the periventricular white matter on the FLAIR and T2 images (Fig. 2a, 2b and 2c); These lesions are bright spots on the aforementioned images. Cervical MRI was unremarkable.

The cerebral vascular reactivity assessed with acetazolamide brain perfusion SPET with technetium- $^{99m}$  ethyl cysteinate dimer ( $^{99m}\text{Tc}$ -ECD) was also performed and revealed no perfusion abnormality (Fig. 3). Because the acetazolamide stress brain perfusion SPET was within normal limits, basal brain perfusion SPET was not important.

Susac et al in 2003 reported the largest series of cases of a syndrome that bears Susac's name that is 27 cases studied by magnetic resonance imaging (MRI). They reviewed that the character of lesions on FLAIR and on T2 sequences consisted of small well-demarcated, spherical, high-signal-intensity lesions located in the body and splenium of corpus callosum and further attributed to microinfarctions [7]. The size of the callosal lesions is usually 3-7mm, suggesting occlusion of small (under 100 $\mu\text{m}$ ), precapillary arterioles [8]. This

small size is beyond the resolution of arteriography, which is almost always normal in patients with SS [7, 9].

Diffusion-weighted imaging and apparent diffusion coefficients have been proved to be sensitive to histologic and physiologic changes associated with brain infarction and useful in differentiating acute from chronic lesions in Susac's syndrome [10, 11]. On the other hand, Xu et al (2004) reported one case of Susac's syndrome in which perfusion MRI, did not reveal any areas of decreased perfusion. The authors suggested that their study was performed months after the initial presentation, when the patient was in remission and presumably, no longer suffering from cerebral ischemia [12].

Others have reported brain SPET hypoperfusion in 100% and 45% of SLE patients with and without abnormal brain MRI, respectively [13]. Others have reported APS cases who showed hypoperfusion lesions on brain SPET with technetium-99m hexamethylpropylene amine oxime and no obvious abnormalities on MRI [14, 15]. Microscopic brain examination of APS patients shows occlusion of small brain vessels caused by fibrin thrombi or endothelial proliferation in the vessel lumen [16] which explain the hypoperfusion findings of APS patients on brain SPET [14, 15].

As our knowledge, in the first study with fluoro-deoxy-glucose positron emission tomography (FDG-PET), marked hypometabolism in the right frontal, parietal and temporal lobes was shown [17]. In that case, the hypometabolism on PET was more extensive rather than on conventional MRI, suggesting that positron emission tomography (PET) may be complementary to other diagnostic techniques in the evaluation of SS.

In our case, unlike to a connective tissue disorder with neurologic manifestations and usually an abnormal perfusion scan, brain SPET with <sup>99m</sup>Tc-ECD and acetazolamid enhancement were normal. The small volume involvement of brain parenchyma and also the early stage of the disease might explain the absence of such abnormalities in the acetazolamid-challenged SPET. Furthermore, the study was performed after corticosteroid treatment, which may have lead to patrol remission during which the patient was not suffering from cerebral ischemia. *In conclusion*, brain SPET with <sup>99m</sup>Tc-ECD-acetazolamid enhancement in this case of SS was normal. The small volume involvement of brain parenchyma, the early stage of the disease and treatment with steroids might explain normal findings.

## Bibliography

1. Aubart-Cohen F, Klein I, Alexandra JF et al. Long-term outcome in Susac syndrome. *Medicine (Baltimore)*. 2007; 86: 93-102.
2. O'Halloran HS, Pearson PA, Lee WB et al. Microangiopathy of the brain, retina, and cochlea (Susac syndrome). A report of five cases and a review of the literature. *Ophthalmology*. 1998; 105: 1038-44.
3. Kleffner I, Deppe M, Mohammadi S et al. Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. *Neurology*. 2008; 70: 1867-9.
4. Dorr J, Radbruch H, Bock M et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. *Nat Rev Neurol*. 2009; 5: 683-8.

5. Susac JO. Susac's syndrome. *AJNR Am J Neuroradiol*. 2004; 25: 351-2.
6. Sandhya V, Anand N. Susac syndrome. *Eye (Lond)*. 2002; 16: 788-90.
7. Susac JO, Murtagh FR, Egan RA et al. MRI findings in Susac's syndrome. *Neurology*. 2003; 61: 1783-7.
8. Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. *AJNR Am J Neuroradiol*. 1990; 11: 431-9.
9. Saw VP, Canty PA, Green CM et al. Susac syndrome: microangiopathy of the retina, cochlea and brain. *Clin Experiment Ophthalmol*. 2000; 28: 373-81.
10. Allmendinger AM, Spektor V, Destian S. CT and MR imaging of Susac syndrome in a young male presenting with acute disorientation. *Clin Imaging*. 2010; 34: 138-42.
11. White ML, Zhang Y, Smoker WR. Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. *AJNR Am J Neuroradiol*. 2004; 25: 706-13.
12. Xu MS, Tan CB, Umapathi T, Lim CC. Susac syndrome: serial diffusion-weighted MR imaging. *Magn Reson Imaging*. 2004; 22: 1295-8.
13. Chen JJ, Yen RF, Kao A et al. Abnormal regional cerebral blood flow found by technetium-99m ethyl cysteinate dimer brain single photon emission computed tomography in systemic lupus erythematosus patients with normal brain MRI findings. *Clin Rheumatol*. 2002; 21: 516-9.
14. Kao CH, Lan JL, Hsieh JF et al. Evaluation of regional cerebral blood flow with <sup>99m</sup>Tc-HMPAO in primary antiphospholipid antibody syndrome. *J Nucl Med*. 1999; 40: 1446-50.
15. Kato T, Morita A, Matsumoto Y. Hypoperfusion of brain single photon emission computerized tomography in patients with antiphospholipid antibodies. *J Dermatol Sci*. 1997; 14: 20-8.
16. Hughson MD, McCarty GA, Sholer CM, Brumback RA. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome. *Mod Pathol*. 1993; 6: 644-53.
17. Dielman C, Laureys G, Meurs A et al. Susac syndrome: a case report and PET imaging findings. *Acta Neurol Belg*. 2009; 109: 226-30.

**Majid Assadi<sup>1</sup> MD, Hooman Salimipour<sup>2</sup> MD, Iraj Nabipour<sup>1</sup> MD, Reza Nemati<sup>2</sup> MD, Jamshid Saberifard<sup>3</sup> MD, Mohammad Seyedabadi<sup>1</sup>, PhD**

1. Bushehr Research Center for Nuclear Medicine, The Persian Gulf Biomedical Sciences Institute, Bushehr University of Medical Sciences, Bushehr, Iran
2. Department of Neurology and 3. Radiology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

**Majid Assadi, MD,**

Bushehr Research Center for Nuclear Medicine,  
The Persian Gulf Biomedical Sciences Institute,  
Boostan 19 Alley, Imam Khomeini Street,  
Bushehr, Iran  
Tel: 0098-771-2580169  
Fax: 0098-771-2541828  
E-mail: assadipoya@yahoo.com

*Hell J Nucl Med* 2010; 13(3): 291-292  
Published on line: 25-11-10